Jane Street’s Theriva Biologics TOVX Stock Holding History

Jane Street’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.7K	Buy	+177,034	New	+$34.9K	﹤0.01%	11078
2025 Q4	–	Sell	-36,771	Closed	-$14.9K	–	12393
2025 Q3	$14.9K	Buy	+36,771	New	+$15.9K	﹤0.01%	10561
2024 Q1	–	Sell	-1,902	Closed	-$20.5K	–	10084
2023 Q4	$20.5K	Buy	1,902 +1,209	+174%	+$14.9K	﹤0.01%	8907
2023 Q3	$9.35K	Buy	+693	New	+$10.5K	﹤0.01%	8392
2022 Q2	–	Sell	-1,127	Closed	-$80K	–	10891
2022 Q1	$80K	Buy	+1,127	New	+$76.8K	﹤0.01%	9539
2018 Q4	–	Sell	-75	Closed	-$49K	–	5719
2018 Q3	$49K	Buy	+75	New	+$82.9K	﹤0.01%	4927
2016 Q1	–	Sell	-3	Closed	-$64K	–	4643
2015 Q4	$64K	Buy	+3	New	+$63.5K	﹤0.01%	3848
2015 Q3	–	Sell	-3	Closed	-$70K	–	4147
2015 Q2	$70K	Buy	+3	New	+$60.2K	﹤0.01%	3490

Other funds holding TOVX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street's TOVX Position: Q1 2026 in Review

Jane Street opened a new position in Theriva Biologics (TOVX) in Q1 2026: 177,034 shares worth $34.7K. The stake represents ﹤0.01% of the portfolio and ranks #11078 among its holdings. This is a return to the name: Jane Street previously reported a position in TOVX as recently as Q3 2025.

Jane Street first reported a position in TOVX in Q2 2015 and has held it in 8 quarters since. The position peaked at $80K in Q1 2022. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

Jane Street held 177,034 shares of Theriva Biologics worth $34.7K as of Q1 2026.
Theriva Biologics was a new Jane Street position in Q1 2026.
Theriva Biologics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11078 holding.
Jane Street first reported a position in Theriva Biologics in Q2 2015 and has held it in 8 quarters since.
Jane Street's Theriva Biologics position peaked at $80K in Q1 2022.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.